

Online supplement

List of studies excluded due to less than three publication from the same model or did not model mortality as outcome:

1. Akushevich I, Kravchenko JS, Manton KG: Health-based population forecasting: effects of smoking on mortality and fertility. *Risk Analysis* 2007, 27(2):467-482.
2. Apelberg BJ, Onicescu G, Avila-Tang E, Samet JM: Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States. *American Journal of Public Health* 2010, 100(2):341-348.
3. Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J: Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece. *Clinical Therapeutics* 2012, 34(8):1803-1814.
4. Avila-Tang E, Apelberg BJ, Yamaguchi N, Katanoda K, Sobue T, Samet JM: Modelling the health benefits of smoking cessation in Japan. *Tobacco Control* 2009, 18(1):10-17.
5. Bachand AM, Sulsky SI, Curtin GM: Assessing the Likelihood and Magnitude of a Population Health Benefit Following the Market Introduction of a Modified-Risk Tobacco Product: Enhancements to the Dynamic Population Modeler, DPM(+1). *Risk Analysis* 2018, 38(1):151-162.
6. Baker CL, Ferrufino CP, Bruno M, Kowal S: Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers. *Advances in Therapy* 2017, 34(1):156-170.
7. Bala M: [Determining the possibility of collecting reliable data for use in decision making in health care on the example of cost-effectiveness analysis of methods used in smoking cessation]. *Przegląd Lekarski* 2004, 61(10):1180-1183.
8. Banegas Banegas JR, Rodriguez Artalejo F, Martin-Moreno JM, Gonzalez Enriquez J, Villar Alvarez F, Guasch Aguilar A: [Projections of the impact of the smoking habit on the health of the Spanish population and on the potential benefits from its control]. *Medicina Clinica* 1993, 101(17):644-649.
9. Bardach A, Canete F, Sequera VG, Palacios A, Alcaraz A, Rodriguez B, Caporale J, Augustovski F, Pichon-Riviere A: [Burden of disease attributable to tobacco use in Paraguay, and potential health and financial impact of increasing prices through taxing]. *Revista Peruana de Medicina Experimental y Salud Publica* 2018, 35(4):599-609.
10. Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, Hiscock R: One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. *Nicotine & Tobacco Research* 2011, 13(2):135-145.
11. Berardi V, Carretero-Gonzalez R, Bellettiere J, Adams MA, Hughes S, Hovell M: A Markov approach for increasing precision in the assessment of data-intensive behavioral interventions. *Journal of Biomedical Informatics* 2018, 85:93-105.
12. Bronnum-Hansen H: [Predicted effect of smoking cessation of tobacco-related mortality]. *Ugeskrift for Laeger* 2000, 162(43):5772-5777.
13. Cadier B, Durand-Zaleski I, Thomas D, Chevreur K: Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases. *PLoS ONE* 2016, 11(2):e0148750.
14. Cadilhac DA, Magnus A, Sheppard L, Cumming TB, Pearce DC, Carter R: The societal benefits of reducing six behavioural risk factors: an economic modelling study from Australia. *BMC Public Health* 2011, 11:483.

15. Chevreul K, Cadier B, Durand-Zaleski I, Chan E, Thomas D: Cost effectiveness of full coverage of the medical management of smoking cessation in France. *Tobacco Control* 2014, 23(3):223-230.
16. Cornuz J, Gilbert A, Pinget C, McDonald P, Slama K, Salto E, Paccaud F: Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. *Tobacco Control* 2006, 15(3):152-159.
17. Cornuz J, Pinget C, Gilbert A, Paccaud F: Cost-effectiveness analysis of the first-line therapies for nicotine dependence. *European Journal of Clinical Pharmacology* 2003, 59(3):201-206.
18. Criss SD, Sheehan DF, Palazzo L, Kong CY: Population impact of lung cancer screening in the United States: Projections from a microsimulation model. *PLoS Medicine* 2018, 15(2):e1002506.
19. Croghan IT, Offord KP, Evans RW, Schmidt S, Gomez-Dahl LC, Schroeder DR, Patten CA, Hurt RD: Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. *Mayo Clinic Proceedings* 1997, 72(10):917-924.
20. Dino G, Horn K, Abdulkadri A, Kalsekar I, Branstetter S: Cost-effectiveness analysis of the Not On Tobacco program for adolescent smoking cessation. *Prevention Science* 2008, 9(1):38-46.
21. Djalalov S, Masucci L, Isaranuwachai W, Evans W, Peter A, Truscott R, Cameron E, Mittmann N, Rabeneck L, Chan K et al: Economic evaluation of smoking cessation in Ontario's regional cancer programs. *Cancer Medicine* 2018, 7(9):4765-4772.
22. Emery S, Ake CF, Navarro AM, Kaplan RM: Simulated effect of tobacco tax variation on Latino health in California. *American Journal of Preventive Medicine* 2001, 21(4):278-283.
23. Frisco ML, Van Hook J, Hummer RA: Would the elimination of obesity and smoking reduce U.S. racial/ethnic/nativity disparities in total and healthy life expectancy? *SSM - Population Health* 2019, 7:100374.
24. Getsios D, Marton JP, Revankar N, Ward AJ, Willke RJ, Rublee D, Ishak KJ, Xenakis JG: Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. *PharmacoEconomics* 2013, 31(9):767-780.
25. Gilbert AR, Pinget C, Bovet P, Cornuz J, Shamlaye C, Paccaud F: The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. *Tobacco Control* 2004, 13(2):190-195.
26. Guerrero F, Santonja FJ, Villanueva RJ: Analysing the Spanish smoke-free legislation of 2006: a new method to quantify its impact using a dynamic model. *The International Journal on Drug Policy* 2011, 22(4):247-251.
27. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C: The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. *The European Journal of Health Economics* 2013, 14(5):789-797.
28. Hill A, Camacho OM: A system dynamics modelling approach to assess the impact of launching a new nicotine product on population health outcomes. *Regulatory Toxicology and Pharmacology* 2017, 86:265-278.
29. Ho LM, Schafferer C, Lee JM, Yeh CY, Hsieh CJ: The effect of cigarette price increases on cigarette consumption, tax revenue, and smoking-related death in Africa from 1999 to 2013. *International Journal of Public Health* 2017, 62(8):899-909.
30. Ho LM, Schafferer C, Lee JM, Yeh CY, Hsieh CJ: Raising cigarette excise tax to reduce consumption in low-and middle-income countries of the Asia-Pacific region:a simulation

- of the anticipated health and taxation revenues impacts. *BMC Public Health* 2018, 18(1):1187.
31. Hojgaard B, Olsen KR, Pisinger C, Tonnesen H, Gyrd-Hansen D: The potential of smoking cessation programmes and a smoking ban in public places: comparing gain in life expectancy and cost effectiveness. *Scandinavian Journal of Public Health* 2011, 39(8):785-796.
 32. Honeycutt A, Bradley C, Khavjou O, Yarnoff B, Soler R, Orenstein D: Simulated impacts and potential cost effectiveness of Communities Putting Prevention to Work: Tobacco control interventions in 21 U.S. communities, 2010-2020. *Preventive Medicine* 2019, 120:100-106.
 33. Hu TW, Mao Z, Shi J, Chen W: The role of taxation in tobacco control and its potential economic impact in China. *Tobacco Control* 2010, 19(1):58-64.
 34. Hurley SF, Matthews JP: The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. *Cost Effectiveness and Resource Allocation* 2007, 5:2.
 35. Hurley SF, Matthews JP: Cost-effectiveness of the Australian National Tobacco Campaign. *Tobacco Control* 2008, 17(6):379-384.
 36. Husain MJ, Khondker BH: Tobacco-free economy: A SAM-based multiplier model to quantify the impact of changes in tobacco demand in Bangladesh. *Margin - the Journal of Applied Economic Research* 2016, 10(1):55-85.
 37. Igarashi A, Goto R, Suwa K, Yoshikawa R, Ward AJ, Moller J: Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. *Applied Health Economics and Health Policy* 2016, 14(1):77-87.
 38. Igarashi A, Takuma H, Fukuda T, Tsutani K: Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. *Pharmacoeconomics* 2009, 27(3):247-261.
 39. Johansson PM, Tillgren PE, Guldbbrandsson KA, Lindholm LA: A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. *Scandinavian Journal of Public Health* 2005, 33(5):343-352.
 40. Kalkhoran S, Glantz SA: Modeling the Health Effects of Expanding e-Cigarette Sales in the United States and United Kingdom: A Monte Carlo Analysis. *JAMA Internal Medicine* 2015, 175(10):1671-1680.
 41. Kaplan RM, Ake CF, Emery SL, Navarro AM: Simulated effect of tobacco tax variation on population health in California. *American Journal of Public Health* 2001, 91(2):239-244.
 42. Lawrence WF, Smith SS, Baker TB, Fiore MC: Does over-the-counter nicotine replacement therapy improve smokers' life expectancy? *Tobacco Control* 1998, 7(4):364-368.
 43. Leung W, Roberts V, Gordon LG, Bullen C, McRobbie H, Prapavessis H, Jiang Y, Maddison R: Economic evaluation of an exercise-counselling intervention to enhance smoking cessation outcomes: The Fit2Quit trial. *Tobacco Induced Diseases* 2017, 15:21.
 44. Li Y, Zeng X, Liu J, Liu Y, Liu S, Yin P, Qi J, Zhao Z, Yu S, Hu Y et al: Can China achieve a one-third reduction in premature mortality from non-communicable diseases by 2030? *BMC Medicine* 2017, 15(1):132.
 45. Lock K, Wilson K, Murphy D, Riesco JA: A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. *Expert Opinion on Pharmacotherapy* 2011, 12(17):2613-2626.

46. Mejia AB, Ling PM, Glantz SA: Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. *Tobacco Control* 2010, 19(4):297-305.
47. Minh HV, Duyen NT, Ngan TT, Ngoc NB, Son DT, Hai PT: Potential health impacts of increasing the cigarette tax in Viet Nam. *The International Journal of Tuberculosis and Lung Disease* 2018, 22(11):1378-1382.
48. Muhammad-Kah RS, Pithawalla YB, Boone EL, Wei L, Jones MA, Black RA, Bryan TM, Sarkar MA: A Computational Model for Assessing the Population Health Impact of Introducing a Modified Risk Claim on an Existing Smokeless Tobacco Product. *International Journal of Environmental Research and Public Health* 2019, 16(7).
49. Neovius K, Rasmussen F, Sundstrom J, Neovius M: Forecast of future premature mortality as a result of trends in obesity and smoking: nationwide cohort simulation study. *European Journal of Epidemiology* 2010, 25(10):703-709.
50. Nohlert E, Helgason AR, Tillgren P, Tegelberg A, Johansson P: Comparison of the cost-effectiveness of a high- and a low-intensity smoking cessation intervention in Sweden: a randomized trial. *Nicotine & Tobacco Research* 2013, 15(9):1519-1527.
51. Ong MK, Glantz SA: Free nicotine replacement therapy programs vs implementing smoke-free workplaces: a cost-effectiveness comparison. *American Journal of Public Health* 2005, 95(6):969-975.
52. Owen AJ, Maulida SB, Zomer E, Liew D: Productivity burden of smoking in Australia: a life table modelling study. *Tobacco Control* 2018.
53. Pennington B, Filby A, Owen L, Taylor M: Smoking Cessation: A Comparison of Two Model Structures. *PharmacoEconomics* 2018, 36(9):1101-1112.
54. Pichon-Riviere A, Augustovski F, Bardach A, Colantonio L: Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America. *Value in Health* 2011, 14(5 Suppl 1):S51-59.
55. Pinget C, Martin E, Wasserfallen JB, Humair JP, Cornuz J: Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling. *European Journal of Cardiovascular Prevention and Rehabilitation* 2007, 14(3):451-455.
56. Poland B, Teischinger F: Population Modeling of Modified Risk Tobacco Products Accounting for Smoking Reduction and Gradual Transitions of Relative Risk. *Nicotine & Tobacco Research* 2017, 19(11):1277-1283.
57. Popp J, Nyman JA, Luo X, Bengtson J, Lust K, An L, Ahluwalia JS, Thomas JL: Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students. *The European Journal of Health Economics* 2018, 19(9):1319-1333.
58. Soneji SS, Sung HY, Primack BA, Pierce JP, Sargent JD: Quantifying population-level health benefits and harms of e-cigarette use in the United States. *PLoS ONE* 2018, 13(3):e0193328.
59. Song F, Elwell-Sutton T, Naughton F: Impact of the NHS stop smoking services on smoking prevalence in England: a simulation modelling evaluation. *Tobacco Control* 2018.
60. Sonntag D, Gilbody S, Winkler V, Ali S: German EstSmoke: estimating adult smoking-related costs and consequences of smoking cessation for Germany. *Addiction* 2018, 113(1):125-136.
61. Stenholm S, Head J, Kivimaki M, Kawachi I, Aalto V, Zins M, Goldberg M, Zaninotto P, Magnuson Hanson L, Westerlund H et al: Smoking, physical inactivity and obesity as predictors of healthy and disease-free life expectancy between ages 50 and 75: a multicohort study. *International Journal of Epidemiology* 2016, 45(4):1260-1270.

62. Stewart ST, Cutler DM, Rosen AB: Forecasting the effects of obesity and smoking on U.S. life expectancy. *The New England Journal of Medicine* 2009, 361(23):2252-2260.
63. Thavorn K, Chaiyakunapruk N: A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. *Tobacco Control* 2008, 17(3):177-182.
64. Tobias MI, Cavana RY, Bloomfield A: Application of a system dynamics model to inform investment in smoking cessation services in New Zealand. *American Journal of Public Health* 2010, 100(7):1274-1281.
65. Tosanguan J, Chaiyakunapruk N: Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand. *Addiction* 2016, 111(2):340-350.
66. van Meijgaard J, Fielding JE: Estimating benefits of past, current, and future reductions in smoking rates using a comprehensive model with competing causes of death. *Preventing Chronic Disease* 2012, 9:E122.
67. van Walbeek C: A simulation model to predict the fiscal and public health impact of a change in cigarette excise taxes. *Tobacco Control* 2010, 19(1):31-36.
68. Vugrin ED, Rostron BL, Verzi SJ, Brodsky NS, Brown TJ, Choiniere CJ, Coleman BN, Paredes A, Apelberg BJ: Modeling the potential effects of new tobacco products and policies: a dynamic population model for multiple product use and harm. *PLoS ONE* 2015, 10(3):e0121008.
69. Yang W, Dall TM, Zhang Y, Zhang S, Arday DR, Dorn PW, Jain A: Simulation of quitting smoking in the military shows higher lifetime medical spending more than offset by productivity gains. *Health Affairs* 2012, 31(12):2717-2726.
70. Yang W, Zou Q, Tan E, Watkins L, Beronja K, Hogan PF, Elenberg K: Future Health and Economic Impact of Comprehensive Tobacco Control in DoD: A Microsimulation Approach. *Military Medicine* 2018, 183(1-2):e104-e112.
71. Ye CY, Lee JM, Chen SH: Economic gains and health benefits from a new cigarette tax scheme in Taiwan: a simulation using the CGE model. *BMC public health* 2006, 6:62.
72. Yeh CY, Schafferer C, Lee JM, Ho LM, Hsieh CJ: The effects of a rise in cigarette price on cigarette consumption, tobacco taxation revenues, and of smoking-related deaths in 28 EU countries-- applying threshold regression modelling. *BMC Public Health* 2017, 17(1):676.